



Dr June Raine CBE
Chief Executive
Medicines and Healthcare products Regulatory Agency

13 May 2020

Via e-mail: june.raine@mhra.gov.uk

Dear Dr Raine,

On behalf of People for the Ethical Treatment of Animals (PETA) Foundation and our more than 1.3 million members and supporters, I am writing to express our strong support of the Medicines and Healthcare products Regulatory Agency's (MHRA) policies that aim to expedite the development of safe, effective COVID-19 therapies using modern, human-relevant testing strategies. In addition to fostering the rapid development of treatments, vaccines, and diagnostic tools to address this pandemic, these policies present an unparalleled opportunity to improve the processes used by industry and regulatory agencies to develop new medical treatments.

Prioritise Human-Relevant Methods

We welcome MHRA's commitment to applying the 3Rs in the regulatory testing of medicinal products and applaud its work to date with the National Centre for the 3Rs in promoting the use of human tissue for safety pharmacology.¹ Now, perhaps more than ever before, people need strategies that will bring medical products to market faster and with greater assurances of safety. Replacing reliance on animal testing with new tools and technology that better predict human responses is one such strategy. We therefore ask that you consider prioritising this commitment in light of the COVID-19 pandemic.

As stated in the summary report from the first Global Regulatory Workshop on COVID-19 Vaccine Development of the International Coalition of Medicines Regulatory Authorities,² of which MHRA is a member, "[t]he rapid spread of SARS-CoV-2 requires accelerated development timelines for SARS-CoV-2 vaccine candidates to enter expeditiously into Phase 1 clinical trials". The workshop identified that some preclinical data usually required prior to human trials could be bypassed without jeopardising human health where an established platform technology is used. Indeed, the US Food and Drug Administration took this approach in its review of the investigational new drug application for the COVID-19 vaccine candidate jointly developed by Moderna and the US National Institutes of Health,³ which allowed the vaccine to enter clinical trials without first undergoing the routine suite of animal tests. We suspect this may have also been the case with other vaccines.^{4,5} We support these decisions and request that this approach be extended beyond COVID-19 to cover the development of all drugs.

PEOPLE FOR
THE ETHICAL
TREATMENT
OF ANIMALS

PO Box 70315
London N1P 2RG
United Kingdom
+44 (0) 20 7837 6327
+44 (0) 20 7923 6242 (fax)

Info@peta.org.uk

PEOPLE FOR THE ETHICAL
TREATMENT OF ANIMALS (PETA)
FOUNDATION – a charitable
company limited by guarantee,
with its registered office at
Cannon Place, 78 Cannon Street,
London EC4N 6AF.
Registered in England and Wales
as charity number 1056453,
company number 3135903.

Affiliates

- PETA US
- PETA Asia
- PETA India
- PETA France
- PETA Australia
- PETA Germany
- PETA Netherlands

Avoid Falling Back on Old Methods

Regulatory agencies around the world are responding to the urgency of this crisis by granting new drug sponsors flexibility in proposing innovative strategies that replace animal use. As MHRA moves forward, we urge you to leverage the lessons learned during the coronavirus pandemic to expedite acceptance of modern toxicological methods that assure new therapies are safe, effective, and accessible. As illustrated by the rapid movement towards clinical trials of vaccines and therapies such as human convalescent plasma,⁶ MHRA must seize this opportunity to take decisive action to support its goals of modernising and accelerating drug development by pivoting towards the use of available human-relevant, animal-free test methods.

In the existing process, more than 95% of new drugs that pass currently required animal tests ultimately fail in humans.⁷ The coronavirus pandemic has emphasised the need to replace the lengthy, animal-intensive drug development process with an approach that efficiently and effectively identifies life-saving human treatments. We applaud MHRA's role in pushing humane science forward during this pandemic and call on the agency to continue prioritising a transition to human-relevant methods well beyond COVID-19.

I would appreciate it if, at your earliest convenience, you would inform me of MHRA's plans to integrate these recent policy changes in response to COVID-19 into the agency's broader approach to the development and testing of new therapies. If you are available for a teleconference to discuss this important matter, please let me know. I can be reached at SamanthaSaunders@peta.org.uk.

Sincerely,



Samantha Saunders, PhD
Research Associate

¹Holmes A, Bonner F, & Jones D. Assessing drug safety in human tissues – what are the barriers? *Nat Rev Drug Discov*. 2015;14(8):585–587. <https://doi.org/10.1038/nrd4662>

²International Coalition of Medicines Regulatory Authorities. Global regulatory workshop on COVID-19 vaccine development: Summary report. 2020. http://www.icmra.info/drupal/sites/default/files/2020-03/First%20regulatory%20COVID-19%20workshop%20-%20meeting%20report_March%202020.pdf. Accessed 13 May 2020.

³Moderna. Moderna's work on a potential vaccine against COVID-19. <https://www.modernatx.com/modernas-work-potential-vaccine-against-covid-19>. Accessed 13 May 2020.

⁴Lane R, Sarah Gilbert: carving a path towards a COVID-19 vaccine. *Lancet*. 2020;395(10232):1247. [https://doi.org/10.1016/S0140-6736\(20\)30796-0](https://doi.org/10.1016/S0140-6736(20)30796-0).

⁵Sample I. Trials to begin on Covid-19 vaccine in UK next month. *The Guardian*. 19 March 2020. <https://www.theguardian.com/society/2020/mar/19/uk-drive-develop-coronavirus-vaccine-science>. Accessed 13 May 2020.

⁶EudraCT Number 2020-001310-38. EU Clinical Trials Register. <https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001310-38/DE>. Accessed 13 May 2020.

⁷Hartung T. Look back in anger – what clinical studies tell us about preclinical work. *ALTEX*. 2013;30(3):275-291. <https://doi.org/10.14573/altex.2013.3.275>.